OKUR — Onkure Therapeutics Balance Sheet
0.000.00%
- $33.60m
- -$77.16m
- 27
- 53
- 22
- 25
Annual balance sheet for Onkure Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 53.6 | 148 | 101 | 103 | 111 |
Prepaid Expenses | |||||
Total Current Assets | 55 | 154 | 106 | 107 | 113 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.069 | 0.212 | 1.75 | 0.733 | 1.79 |
Other Long Term Assets | |||||
Total Assets | 55.2 | 154 | 108 | 107 | 115 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 4.58 | 6.2 | 7.12 | 18.2 | 10.5 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 4.62 | 6.81 | 8.21 | 18.8 | 11.1 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 50.6 | 147 | 100 | 88.6 | 104 |
Total Liabilities & Shareholders' Equity | 55.2 | 154 | 108 | 107 | 115 |
Total Common Shares Outstanding |